Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Sophia G. Liva, Christopher C. Coss, Jiang Wang, William Blum, Rebecca Klisovic, Bhavana Bhatnagar, Katherine Walsh, Susan Geyer, Qiuhong Zhao, Ramiro Garzon, Guido Marcucci, Mitch A. Phelps & Alison R. Walker. (2020) Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leukemia & Lymphoma 61:6, pages 1484-1492.
Read now
Read now
Guldane Cengiz Seval & Meral Beksac. (2019) A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opinion on Drug Safety 18:7, pages 563-571.
Read now
Read now
Bolun Wang, Hui Lyu, Shanshan Pei, Deye Song, Jiangdong Ni & Bolin Liu. (2018) Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle 17:8, pages 985-996.
Read now
Read now
Douglas W. Sborov, Alessandro Canella, Erinn M. Hade, Xiaokui Mo, Soun Khountham, Jiang Wang, Wenjun Ni, Ming Poi, Christopher Coss, Zhongfa Liu, Mitch A. Phelps, Amir Mortazavi, Leslie Andritsos, Robert A. Baiocchi, Beth A. Christian, Don M. Benson, Joseph Flynn, Pierluigi Porcu, John C. Byrd, Flavia Pichiorri & Craig C. Hofmeister. (2017) A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & Lymphoma 58:10, pages 2310-2318.
Read now
Read now
Jacob P. Laubach, Jesus F. San-Miguel, Vania Hungria, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Melissa Alsina & Paul G. Richardson. (2017) Deacetylase inhibitors: an advance in myeloma therapy?. Expert Review of Hematology 10:3, pages 229-237.
Read now
Read now
Kimberly A Redic, Shannon M Hough & Erika M Price. (2016) Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. OncoTargets and Therapy 9, pages 2783-2793.
Read now
Read now
Susmitha Apuri & Lubomir Sokol. (2016) An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 25:6, pages 687-696.
Read now
Read now
Paul G Richardson, R Donald Harvey, Jacob P Laubach, Philippe Moreau, Sagar Lonial & Jesús F San-Miguel. (2016) Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Review of Clinical Pharmacology 9:1, pages 35-48.
Read now
Read now
Hanna Bailey, David D Stenehjem & Sunil Sharma. (2015) Panobinostat for the treatment of multiple myeloma: the evidence to date. Journal of Blood Medicine 6, pages 269-276.
Read now
Read now
Paul G Richardson, Jacob P Laubach, Sagar Lonial, Philippe Moreau, Sung-Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksac, Melissa Alsina & Jesús F San-Miguel. (2015) Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Review of Anticancer Therapy 15:7, pages 737-748.
Read now
Read now
Minal Surati, Kelly Valla, Katherine Sanvidge Shah, Elyse Hall Panjic & Sagar Lonial. (2015) Panobinostat for the treatment of multiple myeloma. Expert Opinion on Orphan Drugs 3:2, pages 229-238.
Read now
Read now
Edward N Libby, Pamela S Becker, Nicholas Burwick, Damian J Green, Leona Holmberg & William Ira Bensinger. (2015) Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Review of Hematology 8:1, pages 9-18.
Read now
Read now
Jacob P Laubach, Peter M Voorhees, Hani Hassoun, Andrzej Jakubowiak, Sagar Lonial & Paul G Richardson. (2014) Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology 7:1, pages 97-111.
Read now
Read now
Enrique M Ocio, Constantine S Mitsiades, Robert Z Orlowski & Kenneth C Anderson. (2014) Future agents and treatment directions in multiple myeloma. Expert Review of Hematology 7:1, pages 127-141.
Read now
Read now
H. Miles Prince. (2012) Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials. Leukemia & Lymphoma 53:9, pages 1658-1659.
Read now
Read now
Articles from other publishers (87)
Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima & Masahiro Abe. (2023) Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood Advances 7:6, pages 1019-1032.
Crossref
Crossref
Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier & Joshua Richter. (2023) Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars in Oncology 50:1-2, pages 40-48.
Crossref
Crossref
Reeder M. Robinson, Ashton P. Basar, Leticia Reyes, Ravyn M. Duncan, Hong Li & Nathan G. Dolloff. (2022) PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma. Cancer Chemotherapy and Pharmacology 89:5, pages 643-653.
Crossref
Crossref
Yu-bo Zhou, Yang-ming Zhang, Hong-hui Huang, Li-jing Shen, Xiao-feng Han, Xiao-bei Hu, Song-da Yu, An-hui Gao, Li Sheng, Ming-bo Su, Xiao-li Wei, Yue Zhang, Yi-fan Zhang, Zhi-wei Gao, Xiao-yan Chen, Fa-jun Nan, Jia Li & Jian Hou. (2021) Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharmacologica Sinica 43:4, pages 1091-1099.
Crossref
Crossref
Monica Epstein & Candis Morrison. (2022) Practical guidance for new multiple myeloma treatment regimens: A nursing perspective. Seminars in Oncology 49:1, pages 103-117.
Crossref
Crossref
Sachi Singhal & Shaji Kumar. (2022) Oral Therapies for Multiple Myeloma. Oncology & Haematology 18:2, pages 139.
Crossref
Crossref
Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton & Graham P. Collins. (2021) A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. BMC Cancer 21:1.
Crossref
Crossref
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov & Helgi B. Schiöth. (2021) Recent developments of HDAC inhibitors: Emerging indications and novel molecules. British Journal of Clinical Pharmacology 87:12, pages 4577-4597.
Crossref
Crossref
Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson & Ajai Chari. (2021) Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:11, pages 752-765.
Crossref
Crossref
Arthur Bobin, Cécile Gruchet, Stéphanie Guidez, Hélène Gardeney, Laly Nsiala Makunza, Mathilde Vonfeld, Anthony Lévy, Laura Cailly, Florence Sabirou, Thomas Systchenko, Niels Moya & Xavier Leleu. (2021) Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article. Cancers 13:20, pages 5210.
Crossref
Crossref
Jacqueline Schütt, Theresa Nägler, Tino Schenk & Annamaria Brioli. (2021) Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers 13:16, pages 4069.
Crossref
Crossref
Sridurga Mithraprabhu, Anna Kalff, Kate H. Gartlan, Ioanna Savvidou, Tiffany Khong, Malarmathy Ramachandran, Rachel E. Cooke, Kathryn Bowen, Geoffrey R. Hill, John Reynolds & Andrew Spencer. (2020) Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma. British Journal of Haematology 193:1, pages 160-170.
Crossref
Crossref
Uros Markovic, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Anna Bulla, Marina Silvia Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo & Concetta Conticello. (2021) Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in Oncology 11.
Crossref
Crossref
Niels van Nieuwenhuijzen, Rowan Frunt, Anne M. May & Monique C. Minnema. (2021) Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. Blood Cancer Journal 11:3.
Crossref
Crossref
Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Terpos & Meletios Athanasios Dimopoulos. (2020) Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology 2020, pages 1-11.
Crossref
Crossref
Ying Xie, Jing Liu, Hongmei Jiang, Jingya Wang, Xin Li, Jingjing Wang, Shuai Zhu, Jing Guo, Tao Li, Yuping Zhong, Qiguo Zhang & Zhiqiang Liu. (2019) Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene 39:4, pages 922-934.
Crossref
Crossref
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, Jean-Luc Harousseau & Mohamad Mohty. (2019) Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia 33:10, pages 2343-2357.
Crossref
Crossref
Katia Beider, Hanna Bitner, Valeria Voevoda-Dimenshtein, Evgenia Rosenberg, Yaarit Sirovsky, Hila Magen, Jonathan Canaani, Olga Ostrovsky, Noya Shilo, Avichai Shimoni, Michal Abraham, Lola Weiss, Michael Milyavsky, Amnon Peled & Arnon Nagler. (2019) The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Biochemical Pharmacology 168, pages 412-428.
Crossref
Crossref
Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, Mirza Baig, Atlantis Dawn Russ, Sabina Saeed, Muhammad Abu Zar, Faryal Razzaq, Jennifer Carew, Steffan Nawrocki, Hussam Al-Kateb, Nadia Nunes Cavalcante Parr, Ali McBride, Jason Valent & Christy Samaras. (2019) Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 397-405.
Crossref
Crossref
Xiao Gao, Lijing Shen, Xiang Li & Jiaying Liu. (2019) Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials. Experimental and Therapeutic Medicine.
Crossref
Crossref
Rakesh Popat, Sarah R. Brown, Louise Flanagan, Andrew Hall, Walter Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low & Jamie Cavenagh. (2018)
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (
MUK
six open label, multi‐centre phase I/
II
Clinical Trial)
. British Journal of Haematology 185:3, pages 573-578.
Crossref
Crossref
Konstantinos Dimopoulos & Kirsten Grønbæk. (2019) Epigenetic therapy in hematological cancers. APMIS 127:5, pages 316-328.
Crossref
Crossref
Chutima Kunacheewa & Robert Z. Orlowski. (2019) New Drugs in Multiple Myeloma. Annual Review of Medicine 70:1, pages 521-547.
Crossref
Crossref
Jonathan L. Kaufman, Roberto Mina, Andrzej J. Jakubowiak, Todd L. Zimmerman, Jeffrey J. Wolf, Colleen Lewis, Charise Gleason, Cathy Sharp, Thomas Martin, Leonard T. Heffner, Ajay K. Nooka, R. Donald Harvey & Sagar Lonial. (2019) Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer Journal 9:1.
Crossref
Crossref
Sikander Ailawadhi, Kevin R. Kelly, Robert A. Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby & Asher Chanan-Khan. (2019) A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:1, pages 29-34.
Crossref
Crossref
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D AndersonJrJr, Heather J Sutherland, Kwee Yong, Axel Hoos, Michele M Gorczyca, Soumi Lahiri, Zangdong He, Daren J Austin, Joanna B Opalinska & Adam D Cohen. (2018) Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. The Lancet Oncology 19:12, pages 1641-1653.
Crossref
Crossref
Hyungwoo Cho, Dok Hyun Yoon, Kyu-pyo Kim, Kyun-Seop Bae, Won Seog Kim, Hyeon-Seok Eom, Jin Seok Kim, Jung Yong Hong, Seok Jin Kim, Hyewon Lee, Soo-Jeong Kim & Cheolwon Suh. (2018) Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs 36:5, pages 877-885.
Crossref
Crossref
Hanley N. Abramson. (2018) The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 611-627.
Crossref
Crossref
Hiroto Ohguchi, Teru Hideshima & Kenneth C. Anderson. (2018) The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer Journal 8:9.
Crossref
Crossref
Priya Choudhry, Derek Galligan & Arun P. Wiita. (2018) Seeking Convergence and Cure with New Myeloma Therapies. Trends in Cancer 4:8, pages 567-582.
Crossref
Crossref
Christine ChenDavid SiegelMartin GutierrezMeagan JacobyCraig C. Hofmeister, Nashat GabrailRachid Baz, Morten Mau-SorensenJesus G. BerdejaMichael Savona, Lynn Savoie, Suzanne TrudelNuchanan AreethamsirikulT. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham & Donna Reece. (2018) Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 131:8, pages 855-863.
Crossref
Crossref
T Harada, H Ohguchi, Y Grondin, S Kikuchi, M Sagawa, Y-T Tai, R Mazitschek, T Hideshima & K C Anderson. (2017) HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31:12, pages 2670-2677.
Crossref
Crossref
Alessandra Larocca, Roberto Mina, Francesca Gay, Sara Bringhen & Mario Boccadoro. (2017) Emerging drugs and combinations to treat multiple myeloma. Oncotarget 8:36, pages 60656-60672.
Crossref
Crossref
Branka Petricevic, Wolfgang Hilbe & Niklas Zojer. (2017) Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma. memo - Magazine of European Medical Oncology 10:3, pages 159-163.
Crossref
Crossref
Jean Luc Harousseau & Michel Attal. (2017) How I treat first relapse of myeloma. Blood 130:8, pages 963-973.
Crossref
Crossref
Muntasir Mamun Majumder, Raija Silvennoinen, Pekka Anttila, David Tamborero, Samuli Eldfors, Bhagwan Yadav, Riikka Karjalainen, Heikki Kuusanmäki, Juha Lievonen, Alun Parsons, Minna Suvela, Esa Jantunen, Kimmo Porkka & Caroline A. Heckman. (2017) Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget 8:34, pages 56338-56350.
Crossref
Crossref
Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski & David D. Hurd. (2017) Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:7, pages 424-432.
Crossref
Crossref
Saurabh Chhabra. (2017) Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals 10:4, pages 40.
Crossref
Crossref
Bishal Gyawali & Vinay Prasad. (2017) Drugs that lack single-agent activity: are they worth pursuing in combination?. Nature Reviews Clinical Oncology 14:4, pages 193-194.
Crossref
Crossref
Dharshan Sivaraj, Michael M Green & Cristina Gasparetto. (2017) Panobinostat for the management of multiple myeloma. Future Oncology 13:6, pages 477-488.
Crossref
Crossref
Larysa Sanchez, David H. Vesole, Joshua R. Richter, Noa Biran, Elizabeth Bilotti, Laura McBride, Palka Anand, Kristin Ivanovski & David S. Siegel. (2017) A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. British Journal of Haematology 176:3, pages 440-447.
Crossref
Crossref
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke, David L Tamang, Min Yang, Simon S Jones, Catherine A Wheeler, Robert J Markelewicz & Noopur S Raje. (2016) Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. The Lancet Oncology 17:11, pages 1569-1578.
Crossref
Crossref
Takeshi Harada, Teru Hideshima & Kenneth C. Anderson. (2016) Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. International Journal of Hematology 104:3, pages 300-309.
Crossref
Crossref
Sarit E. AssoulineTorsten Holm NielsenStephen YuMiguel AlcaideLauren ChongDavid MacDonaldAxel TosikyanVishal KukretiAbbas KezouhTina Petrogiannis-HaliotisMarco AlbuquerqueDaniel FornikaSepideh AlamoutiRemi FromentCelia M. T. GreenwoodKathleen Klein OrosErrol CamgliogluAyushi SharmaRosa ChristodoulopoulosCaroline Rousseau, Nathalie JohnsonMichael CrumpRyan D. Morin & Koren K. Mann. (2016) Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 128:2, pages 185-194.
Crossref
Crossref
Saad Z. UsmaniBrendan M. WeissTorben PlesnerNizar J. BahlisAndrew BelchSagar LonialHenk M. LokhorstPeter M. VoorheesPaul G. RichardsonAjai ChariA. Kate SasserAmy AxelHuaibao Feng, Clarissa M. UhlarJianping WangImran Khan, Tahamtan AhmadiHareth Nahi. (2016) Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 128:1, pages 37-44.
Crossref
Crossref
S. Thomas, R. Aggarwal, T. Jahan, C. Ryan, T. Troung, A.M. Cripps, P. Raha, K.T. Thurn, S. Chen, J.A. Grabowsky, J. Park, J. Hwang, A. Daud & P.N. Munster. (2016) A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Annals of Oncology 27:5, pages 947-952.
Crossref
Crossref
Hans C. Lee, Tomer M. Mark & Jatin J. Shah. (2016) Practical Approaches to the Management of Dual Refractory Multiple Myeloma. Current Hematologic Malignancy Reports 11:2, pages 148-155.
Crossref
Crossref
Madeleine Duvic & Meletios Dimopoulos. (2016) The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treatment Reviews 43, pages 58-66.
Crossref
Crossref
Sarah L. Greig. (2016) Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Targeted Oncology 11:1, pages 107-114.
Crossref
Crossref
Christa A. Manton, Blake Johnson, Melissa Singh, Cavan P. Bailey, Lisa Bouchier-Hayes & Joya Chandra. (2016) Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Scientific Reports 6:1.
Crossref
Crossref
Sagar Lonial. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias
195
205
.
Salma Afifi, Angela Michael, Mahshid Azimi, Mabel Rodriguez, Nikoletta Lendvai & Ola Landgren. (2015) Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:12, pages 1173-1188.
Crossref
Crossref
Jacob P. Laubach, Philippe Moreau, Jesús F. San-Miguel & Paul G. Richardson. (2015) Panobinostat for the Treatment of Multiple Myeloma. Clinical Cancer Research 21:21, pages 4767-4773.
Crossref
Crossref
A Keith Stewart. (2015) Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncology 11:15, pages 2121-2136.
Crossref
Crossref
Emma M. Smith, Lei Zhang, Brian A. Walker, Emma L. Davenport, Lauren I. Aronson, David Krige, Leon Hooftman, Alan H. Drummond, Gareth J. Morgan & Faith E. Davies. (2013) The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget 6:19, pages 17314-17327.
Crossref
Crossref
Joelle El-Amm & Imad A. Tabbara. (2015) Emerging Therapies in Multiple Myeloma. American Journal of Clinical Oncology 38:3, pages 315-321.
Crossref
Crossref
Marina Savelieva, Margaret M. Woo, Horst Schran, Song Mu, Jerry Nedelman & Renaud Capdeville. (2015) Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. European Journal of Clinical Pharmacology 71:6, pages 663-672.
Crossref
Crossref
Leila Haery, Ryan C. Thompson & Thomas D. Gilmore. (2015) Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6:5-6, pages 184-213.
Crossref
Crossref
Ken Maes, Eva De Smedt, Alboukadel Kassambara, Dirk Hose, Anja Seckinger, Els Van Valckenborgh, Eline Menu, Bernard Klein, Karin Vanderkerken, Jérôme Moreaux & Elke De Bruyne. (2014)
In vivo
treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
. Oncotarget 6:5, pages 3319-3334.
Crossref
Crossref
Sunil Sharma, Petronella O. Witteveen, Martijn P. Lolkema, Dagmar Hess, Hans Gelderblom, Syed A. Hussain, Maria G. Porro, Edward Waldron, Sue-zette Valera & Song Mu. (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemotherapy and Pharmacology 75:1, pages 87-95.
Crossref
Crossref
Akinori Sato, Takako Asano, Makoto Isono, Keiichi Ito & Tomohiko Asano. (2014) Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urology 14:1.
Crossref
Crossref
Claudia V. Andreu-Vieyra & James R. Berenson. (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in Hematology 5:6, pages 197-210.
Crossref
Crossref
Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, Jessica Haug, S. Vincent Rajkumar & Shaji Kumar. (2014) Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leukemia Research 38:11, pages 1358-1366.
Crossref
Crossref
Marije Slingerland, Dagmar Hess, Sally Clive, Sunil Sharma, Per Sandstrom, Niklas Loman, Maria G. Porro, Song Mu, Edward Waldron, Sue-zette Valera & Hans Gelderblom. (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemotherapy and Pharmacology 74:5, pages 1089-1098.
Crossref
Crossref
Cindy Varga, Jacob Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson & Paul G. Richardson. (2014) Novel Targeted Agents in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America 28:5, pages 903-925.
Crossref
Crossref
Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak, Andreas Günther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Paolo Corradini, Suporn Chuncharunee, Je-Jung Lee, Robert L Schlossman, Tatiana Shelekhova, Kwee Yong, Daryl Tan, Tontanai Numbenjapon, Jamie D Cavenagh, Jian Hou, Richard LeBlanc, Hareth Nahi, Lugui Qiu, Hans Salwender, Stefano Pulini, Philippe Moreau, Krzysztof Warzocha, Darrell White, Joan Bladé, WenMing Chen, Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L Kaufman, Enrique M Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich & Paul G Richardson. (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. The Lancet Oncology 15:11, pages 1195-1206.
Crossref
Crossref
Charlotte Pawlyn, Martin F Kaiser, Faith E Davies & Gareth J Morgan. (2014) Current and potential epigenetic targets in multiple myeloma. Epigenomics 6:2, pages 215-228.
Crossref
Crossref
E M Ocio, P G Richardson, S V Rajkumar, A Palumbo, M V Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, K C Anderson, M A Dimopoulos, H Avet-Loiseau, U-H Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, C S Chim, J J Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, W J Chng, P Moreau, P Sonneveld, H Ludwig, B G M Durie & J F S Miguel. (2013) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28:3, pages 525-542.
Crossref
Crossref
S Lonial & K C Anderson. (2013) Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 28:2, pages 258-268.
Crossref
Crossref
Pilar de la Puente, Barbara Muz, Feda Azab, Micah Luderer & Abdel Kareem Azab. (2014) Molecularly Targeted Therapies in Multiple Myeloma. Leukemia Research and Treatment 2014, pages 1-8.
Crossref
Crossref
Alessandra Romano, Concetta Conticello, Maide Cavalli, Calogero Vetro, Cosimo Di Raimondo, Valentina Di Martina, Elena Schinocca, Alessia La Fauci, Nunziatina Laura Parrinello, Annalisa Chiarenza & Francesco Di Raimondo. (2014) Salvage Therapy of Multiple Myeloma: The New Generation Drugs. BioMed Research International 2014, pages 1-14.
Crossref
Crossref
James R. Berenson, James D. Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, Kenneth Dressler, Hassan H. Ghazal, Saad Jamshed, Edwin C. Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift & Robert Vescio. (2013) A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology 93:1, pages 89-98.
Crossref
Crossref
Jason P. Meadows & Tomer M. Mark. (2013) Management of Double-Refractory Multiple Myeloma. Current Hematologic Malignancy Reports 8:4, pages 253-260.
Crossref
Crossref
Jesús F. San-MiguelPaul G. RichardsonAndreas GüntherOrhan SezerDavid SiegelJoan BladéRichard LeBlancHeather SutherlandMonika SopalaKaushal K. MishraSong MuPriscille M. BourquelotMaría Victoria MateosKenneth C. Anderson. (2013) Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology 31:29, pages 3696-3703.
Crossref
Crossref
Philippe Moreau. (2013) Panobinostat to revert bortezomib resistance. Blood 122:14, pages 2292-2293.
Crossref
Crossref
Lenushka Maharaj, Charles M. Marson, Brian J. Middleton, Alf S. Rioja, Jackie Perry, Heather Oakervee, Jamie Cavenagh, Simon P. Joel & Rakesh Popat. (2013) The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models. British Journal of Haematology 163:1, pages 135-139.
Crossref
Crossref
Robert Z. Orlowski. (2013) Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Seminars in Oncology 40:5, pages 634-651.
Crossref
Crossref
J Moreaux, T Reme, W Leonard, J-L Veyrune, G Requirand, H Goldschmidt, D Hose & B Klein. (2013) Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. British Journal of Cancer 109:3, pages 676-685.
Crossref
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Roman Hajek, Ivan Spicka, Meletios A. Dimopoulos, Philippe Moreau, David S. Siegel, Sundar Jagannath & Kenneth C. Anderson. (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research 37:7, pages 829-837.
Crossref
Crossref
Bo Cai, Hui Lyu, Jingcao Huang, Shuiliang Wang, Choon-Kee Lee, Chunji Gao & Bolin Liu. (2013) Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Letters 335:2, pages 343-350.
Crossref
Crossref
Malcolm A. Smith & Peter Houghton. (2013)
A Proposal Regarding Reporting of
In Vitro
Testing Results
. Clinical Cancer Research 19:11, pages 2828-2833.
Crossref
Crossref
Hans C. LeeJatin J. ShahRobert Z. Orlowski. (2013) Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. American Society of Clinical Oncology Educational Book:33, pages e302-e306.
Crossref
Crossref
Ying-Qing Wang & Ze-Hong Miao. (2013) Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Marine Drugs 11:12, pages 903-933.
Crossref
Crossref
Irene M. GhobrialFederico CampigottoTimothy J. Murphy, Erica N. BoswellRanjit BanwaitFeda AzabStacey ChumaJanet KunsmanAmanda DonovanFarzana MasoodDiane WarrenScott Rodig, Kenneth C. AndersonPaul G. RichardsonEdie WellerJeffrey Matous. (2013) Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood 121:8, pages 1296-1303.
Crossref
Crossref
Panagiotis Ntziachristos, Jasper Mullenders, Thomas Trimarchi & Iannis Aifantis. 2013.
1
38
.
Sally Clive, Margaret M. Woo, Thomas Nydam, Lindsay Kelly, Margaret Squier & Mark Kagan. (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemotherapy and Pharmacology 70:4, pages 513-522.
Crossref
Crossref
Philippe Moreau. (2012) The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies. Seminars in Hematology 49, pages S33-S46.
Crossref
Crossref